Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Takayuki Yoshino(University of Tsukuba), Kei Muro(Aichi Cancer Center), Masamitsu Hihara(Takeda (Japan)), Hisatsugu Ohori(Tohoku University Hospital), Kohei Shitara(National Cancer Center Hospital East), Katsuya Tsuchihara(Chiba Cancer Center), Takeo Sato(Kitasato University), Hiroyuki Uetake(National Hospital Organization), Kiwamu Akagi(Kuwait University), Kentaro Yamazaki(Shizuoka Cancer Center), Yoshito Komatsu(Hokkaido University Hospital), Manabu Shiozawa(Kanagawa Prefectural Hospital Organization), Takeshi Naitoh(Kitasato University), Eiji Oki(Kyushu University), Takeshi Kato(Osaka National Hospital), Kouji Yamamoto(Yokohama City University), Hirofumi Yasui(Shizuoka Cancer Center), Jun Watanabe(Yokohama City University Medical Center), Atsushi Ochiai(Tokyo University of Science), Junpei Soeda(Takeda (Japan))
Cited by 69
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k